Saccharide-Polypeptide Conjugate Vaccine for Multi-Serotype Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for Streptococcus pneumoniae do not provide comprehensive coverage against a wide range of serotypes, leaving gaps in protection against invasive pneumococcal disease.
Innovation Solution
Development of a pharmaceutical composition in unit dose form containing a plurality of immunogenic saccharide-polypeptide conjugates, each comprising unique capsular polysaccharides or fragments thereof from various Streptococcus pneumoniae serotypes, conjugated to polypeptides, such as CRM197, to enhance immune response and broaden vaccine coverage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current vaccines are used, then simplicity and ease of manufacture are maintained, but vaccine coverage against multiple serotypes is insufficient
Solution Approach 1:
The patent combines multiple capsular polysaccharides from different Streptococcus pneumoniae serotypes (including 6C, 7C, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 20A, 20B, 22F, 23A, 23B, 24F, 24B, 31, 33F, 33B, 34, 35B, 35F, and 38) into a single conjugate vaccine composition. This merging approach expands serotype coverage from what single-component vaccines provide to a comprehensive multi-serotype formulation, directly resolving the contradiction between vaccine coverage and composition complexity.
Solution Approach 2:
The vaccine composition is designed to provide universal protection against multiple serotypes simultaneously through a single administration. Each capsular polysaccharide is conjugated to a carrier protein, creating multi-functional conjugates that elicit immune responses against diverse serotypes. This universal approach allows one vaccine composition to perform the function of multiple separate vaccines, addressing the coverage limitation while managing complexity through standardized conjugate technology.
2Reliability
If polysaccharide amount is increased, then immune response strength is improved, but vaccine composition complexity and manufacturing difficulty increase
Solution Approach 1:
The patent specifies precise polysaccharide amount ranges (0.5-5 μg per serotype) and conjugate composition parameters to optimize immune response while maintaining manufacturability. By defining specific parameter ranges rather than arbitrary amounts, the invention balances immunogenicity with manufacturing feasibility. The conjugation chemistry parameters are also controlled to ensure consistent immune response across different production batches.
Solution Approach 2:
The vaccine includes polysaccharides from 25 different serotypes, covering more serotypes than any single vaccine previously available. This partial inclusion strategy focuses on the most clinically relevant serotypes that cause invasive disease, providing sufficient immune coverage without including all possible serotypes. The approach delivers excessive coverage relative to previous vaccines while managing manufacturing complexity through selective inclusion of high-priority serotypes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition induces a robust and long-lasting immune response, providing expanded coverage against multiple serotypes, potentially increasing protection against invasive pneumococcal disease beyond existing vaccines.
Implementation Method 1
each comprising individually a capsular polysaccharide, fragment thereof, or combination thereof conjugated to a polypeptide, wherein the capsular polysaccharide, fragment thereof, or combination thereof is from a unique Streptococcus pneumoniae serotype
Data Source
AI summary
Saccharide-polypeptide conjugates, compositions containing these, methods of making and using the conjugates and compositions, and kits containing these, are disclosed.